Clinical Trial Update: Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the safety and tolerability of multiple doses of PF-04950615 (RN316) in adults with hypercholesterolemia. The study has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypercholesterolemia

Drugs mentioned

• PF-04950615 (RN316) (PF-04950615)

Snippet

Sponsor: Pfizer | Conditions: Hypercholesterolemia, Dyslipidemia | Phase 1 | Status: COMPLETED | Results posted: 2019-01-22